Oasmia Pharmaceutical AB is currently, which previously have been communicated, in on-going negotiations with different parties regarding out-licensing of the XR-17 platform as well as the company’s product candidates, with focus on Paclical®/Apealea®. In line with past commercial agreements closed by the company, we see future agreements containing both large signing payments in combination with milestone payments when certain events have occurred and an additional royalty component.
It is hard to predict the timing for finalization of agreements.
The company has not had the opportunity to comment on the article before publication.